LOS ALTOS, Calif. - RenovoRx, Inc. (NASDAQ: RNXT), a developer of targeted oncology therapies with a market capitalization of $28.54 million, has started receiving purchase orders for its RenovoCath device, signaling a key advancement in its commercialization strategy. The company's stock has shown strong momentum, delivering an impressive 83% return over the past year, according to InvestingPro data. The company, which specializes in the Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, has seen over ten medical institutions initiate purchase processes for the RenovoCath device.
The RenovoCath, an FDA-cleared delivery platform for fluids in the peripheral vascular system, is poised to address a range of clinical needs. With an estimated market size of several hundred million dollars in annual sales, RenovoRx is actively exploring ways to meet demand, including potential partnerships with medical device companies. The company maintains a strong financial position with more cash than debt and a healthy current ratio of 5.66, indicating solid short-term liquidity. (InvestingPro subscribers have access to 8 additional key financial insights about RNXT.)
CEO Shaun Bagai expressed confidence in the product's market need, citing over 500 successful uses in clinical trials and the strategic decision to pursue a direct-to-market strategy. RenovoRx has expanded its manufacturing partnership with Medical (TASE:PMCN) Murray to increase device production.
In addition to commercializing RenovoCath, RenovoRx is conducting the Phase III TIGeR-PaC clinical trial for a drug-device combination targeting locally advanced pancreatic cancer. Completion of patient enrollment and interim analysis is expected by the first half of 2025.
Supporting the commercialization efforts, RenovoRx has engaged Richard Stark as a Commercial Advisor. Stark brings over 25 years of experience in medical device commercialization, having held executive roles at Innoblative Designs, Inc. and AngioDynamics (NASDAQ:ANGO).
RenovoCath's potential was highlighted by Dr. Ken Meredith (NYSE:MDP), Medical Director of Sarasota Memorial Health Care System Gastrointestinal Cancer Specialty Program, who noted the significant improvement in tissue concentration with TAMP compared to conventional intravenous delivery.
The information in this report is based on a press release statement from RenovoRx. The company continues to explore other commercial applications for its TAMP technology and RenovoCath delivery system as a standalone device. The future expansion of its delivery system applications could significantly increase the total addressable market for RenovoRx's products. Analyst price targets range from $3.50 to $8.25, suggesting significant potential upside from current levels. Get comprehensive financial analysis and real-time alerts with InvestingPro.
In other recent news, RenovoRx is expanding production of its RenovoCath delivery system, a move driven by increasing demand from oncologists and interventional radiologists. This expansion is backed by a new agreement with Medical Murray, RenovoRx's primary manufacturing partner. The ramped-up production coincides with the company's exploration of commercial opportunities for RenovoCath, independent of ongoing clinical trials.
RenovoRx is currently carrying out the Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer, utilizing its Trans-Arterial Micro-Perfusion (TAMP) therapy platform. The trial aims to demonstrate an overall survival benefit and reduced side effects compared to the current standard of care. The company has recently added more clinical sites to hasten patient enrollment.
The RenovoCath system, which has been used in over 500 procedures, is FDA-approved for isolating blood flow and delivering fluids to selected sites in the peripheral vascular system. CEO Shaun Bagai sees potential clinical applications for RenovoCath beyond pancreatic cancer and expects commercialization efforts to boost revenue by 2025.
Promising early-stage clinical data has been reported for RenovoRx's TAMP therapy in treating locally advanced pancreatic cancer. The Phase III TIGeR-PaC clinical trial is underway to further assess TAMP's efficacy in a larger patient population. These are the recent developments for RenovoRx, with the investigational drug for TAMP therapy, in conjunction with RenovoCath, yet to be approved for commercial sale.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.